Last reviewed · How we verify
Influenza vaccination with PPV23
Influenza vaccination with PPV23, marketed by Korea University Guro Hospital, is a pneumococcal polysaccharide vaccine aimed at preventing invasive pneumococcal disease. The key composition patent is set to expire in 2028, providing a period of exclusive market protection. The primary risk is the potential increase in competition following the patent expiry, which could impact market share and revenue.
At a glance
| Generic name | Influenza vaccination with PPV23 |
|---|---|
| Sponsor | Korea University Guro Hospital |
| Modality | Biologic |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- A Study of Booster Immunization With COVID-19 Vaccine,Inactivated Co -Administration With Influenza Vaccine and Pneumococcal Polysaccharide Vaccine (PHASE4)
- Evaluation of Safety and Immunogenicity of Combined Immunization of PPV23 and IIV4 (PHASE4)
- Combined Immunization of COVID-19 Inactivated Vaccine With QIV and PPV23 (PHASE4)
- Prospective Trial of Vaccine Responses Against Pneumococcus and Influenza in Adult Cancer Patients 65 Years of Age and Older (PHASE2)
- Influenza Vaccine and Pneumococcal Vaccine (PHASE4)
- MF59-adjuvanted Influenza Vaccine and 23-valent Pneumococcal Polysaccharide Vaccine (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Influenza vaccination with PPV23 CI brief — competitive landscape report
- Influenza vaccination with PPV23 updates RSS · CI watch RSS
- Korea University Guro Hospital portfolio CI